Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2006BloodOpen Access

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

Andreas Hochhaus
Andreas HochhausSouth Australia Pathology
Hagop M. Kantarjian
Hagop M. KantarjianThe University of Texas MD Anderson Cancer Center
Michele Baccarani
Michele BaccaraniUniversity of Bergamo

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hochhaus et al. (2006) studied this question.

synapsesocial.com/papers/6a15a5f29b87f33fc69fbb33https://doi.org/10.1182/blood-2006-09-047266
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Confidence Interval for the Median Survival Time1982 · 925 citations
  2. 2Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia1994 · 597 citations
  3. 3The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.2004 · 25 citations
  4. 4Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance2005 · 314 citations
  5. 5Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor2004 · 1,808 citations